{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T20:01:18Z","timestamp":1791576078685,"version":"4.3.4"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,30]]},"DOI":"10.7759\/cureus.89028","type":"journal-article","created":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T07:07:01Z","timestamp":1753859221000},"source":"Crossref","is-referenced-by-count":5,"title":["Evaluation of Effectiveness and Tolerability of Saroglitazar in Metabolic Disease Patients of India: A Retrospective, Observational, Electronic Medical Record-Based Real-World Evidence Study"],"prefix":"10.7759","author":[{"given":"Sambit","family":"Das","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tejal","family":"Lathia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayshree","family":"Swain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachin","family":"Mittal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharad","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahesh","family":"DM","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeraj","family":"Garg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Teja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Beatrice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basavaraj G","family":"Sooragonda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed","family":"Mohd. Razi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashok","family":"Jaiswal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunal S","family":"Jhaveri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Snehal","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garima","family":"Verma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jceh.2019.02.005","article-title":"Screening of cardiovascular disease in nonalcoholic fatty liver disease: whom and how?","volume":"9","author":"Choudhary NS","year":"2019","unstructured":"Choudhary NS, Duseja A. Screening of cardiovascular disease in nonalcoholic fatty liver disease: whom and how?. J Clin Exp Hepatol. 2019, 9:506-14. 10.1016\/j.jceh.2019.02.005","journal-title":"J Clin Exp Hepatol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s00392-020-01709-7","article-title":"NAFLD and cardiovascular diseases: a clinical review","volume":"110","author":"Kasper P","year":"2021","unstructured":"Kasper P, Martin A, Lang S, et al.. NAFLD and cardiovascular diseases: a clinical review. Clin Res Cardiol. 2021, 110:921-37. 10.1007\/s00392-020-01709-7","journal-title":"Clin Res Cardiol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S","article-title":"Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation","volume":"15(7)","author":"Alberti KG","year":"1998","unstructured":"Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. Diabet Med. 1998, 15(7):539 - 553. 10.1002\/(SICI)1096-9136(199807)15:7&lt;539::AID-DIA668&gt;3.0.CO;2-S","journal-title":"Diabet Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s11906-018-0812-z","article-title":"The global epidemic of the metabolic syndrome","volume":"20","author":"Saklayen MG","year":"2018","unstructured":"Saklayen MG. The global epidemic of the metabolic syndrome. Curr Hypertens Rep. 2018, 20:12. 10.1007\/s11906-018-0812-z","journal-title":"Curr Hypertens Rep"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0240971","article-title":"Prevalence of metabolic syndrome among adult population in India: A systematic review and meta-analysis","volume":"15","author":"Krishnamoorthy Y","year":"2020","unstructured":"Krishnamoorthy Y, Rajaa S, Murali S, et al.. Prevalence of metabolic syndrome among adult population in India: A systematic review and meta-analysis. PLoS One. 2020, 15:e0240971. 10.1371\/journal.pone.0240971","journal-title":"PLoS One"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.mjafi.2019.12.001","article-title":"Metabolic syndrome: The Indian public health perspective","volume":"76","author":"Bhalwar R","year":"2020","unstructured":"Bhalwar R. Metabolic syndrome: The Indian public health perspective. Med J Armed Forces India. 2020, 76:8-16. 10.1016\/j.mjafi.2019.12.001","journal-title":"Med J Armed Forces India"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1353\/anq.2016.0055","article-title":"Review of metabolic living: food, fat, and the absorption of illness in India, by Harris Solomon","volume":"89(3)","author":"Wiley AS","year":"2016","unstructured":"Wiley AS. Review of metabolic living: food, fat, and the absorption of illness in India, by Harris Solomon. Anth Qua. 2016, 89(3):935-942. 10.1353\/anq.2016.0055","journal-title":"Anth Qua"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.554961","article-title":"Multi-target approaches in metabolic syndrome","volume":"11","author":"Lillich FF","year":"2020","unstructured":"Lillich FF, Imig JD, Proschak E. Multi-target approaches in metabolic syndrome. Front Pharmacol. 2020, 11:554961. 10.3389\/fphar.2020.554961","journal-title":"Front Pharmacol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1021\/jm0603015","article-title":"The physicochemical challenges of designing multiple ligands","volume":"49","author":"Morphy R","year":"2006","unstructured":"Morphy R, Rankovic Z. The physicochemical challenges of designing multiple ligands. J Med Chem. 2006, 49:4961-70. 10.1021\/jm0603015","journal-title":"J Med Chem"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.2147\/vhrm.s993","article-title":"Peroxisome proliferator-activated receptor-\u03b3 agonists and diabetes: current evidence and future perspectives","volume":"4","author":"Chiarelli F","year":"2008","unstructured":"Chiarelli F, Di Marzio D. Peroxisome proliferator-activated receptor-\u03b3 agonists and diabetes: current evidence and future perspectives. Vasc Health Risk Manag. 2008, 4:297-304. 10.2147\/vhrm.s993","journal-title":"Vasc Health Risk Manag"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-019-0884-3","article-title":"New dual peroxisome proliferator activated receptor agonist-Saroglitazar in diabetic dyslipidemia and non-alcoholic fatty liver disease: integrated analysis of the real world evidence","volume":"18","author":"Kaul U","year":"2019","unstructured":"Kaul U, Parmar D, Manjunath K, et al.. New dual peroxisome proliferator activated receptor agonist-Saroglitazar in diabetic dyslipidemia and non-alcoholic fatty liver disease: integrated analysis of the real world evidence. Cardiovasc Diabetol. 2019, 18:80. 10.1186\/s12933-019-0884-3","journal-title":"Cardiovasc Diabetol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2023.102174","article-title":"Effects of saroglitazar in the treatment of non-alcoholic fatty liver disease or non-alcoholic steatohepatitis: A systematic review and meta-analysis","volume":"47","author":"Bandyopadhyay S","year":"2023","unstructured":"Bandyopadhyay S, Samajdar SS, Das S. Effects of saroglitazar in the treatment of non-alcoholic fatty liver disease or non-alcoholic steatohepatitis: A systematic review and meta-analysis. Clin Res Hepatol Gastroenterol. 2023, 47:102174. 10.1016\/j.clinre.2023.102174","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2013.0253","article-title":"A multicenter, prospective, randomized, double-blind study to evaluate the safety and efficacy of Saroglitazar 2 and 4\u2009mg compared with placebo in type 2 diabetes mellitus patients having hypertriglyceridemia not controlled with atorvastatin therapy (PRESS VI)","volume":"16","author":"Jani RH","year":"2014","unstructured":"Jani RH, Pai V, Jha P, et al.. A multicenter, prospective, randomized, double-blind study to evaluate the safety and efficacy of Saroglitazar 2 and 4\u2009mg compared with placebo in type 2 diabetes mellitus patients having hypertriglyceridemia not controlled with atorvastatin therapy (PRESS VI). Diabetes Technol Ther. 2014, 16:63-71. 10.1089\/dia.2013.0253","journal-title":"Diabetes Technol Ther"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-020-01073-w","article-title":"Effect of saroglitazar 2\u00a0mg and 4\u00a0mg on glycemic control, lipid profile and cardiovascular disease risk in patients with type 2 diabetes mellitus: a 56-week, randomized, double blind, phase 3 study (PRESS XII study)","volume":"19","author":"Krishnappa M","year":"2020","unstructured":"Krishnappa M, Patil K, Parmar K, et al.. Effect of saroglitazar 2\u00a0mg and 4\u00a0mg on glycemic control, lipid profile and cardiovascular disease risk in patients with type 2 diabetes mellitus: a 56-week, randomized, double blind, phase 3 study (PRESS XII study). Cardiovasc Diabetol. 2020, 19:93. 10.1186\/s12933-020-01073-w","journal-title":"Cardiovasc Diabetol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2023.01.018","article-title":"Saroglitazar, a Dual PPAR \u03b1\/\u03b3 Agonist, improves atherogenic dyslipidemia in patients with non-cirrhotic nonalcoholic fatty liver disease: a pooled analysis","volume":"21","author":"Siddiqui MS","year":"2023","unstructured":"Siddiqui MS, Parmar D, Sheikh F, et al.. Saroglitazar, a Dual PPAR \u03b1\/\u03b3 Agonist, improves atherogenic dyslipidemia in patients with non-cirrhotic nonalcoholic fatty liver disease: a pooled analysis. Clin Gastroenterol Hepatol. 2023, 21:2597-2605.e2. 10.1016\/j.cgh.2023.01.018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.9734\/ajmah\/2024\/v22i91085","article-title":"Clinical case series on assessment of therapeutic efficacy of saroglitazar in MASLD patients","volume":"22 (9)","author":"Dang N","year":"2024","unstructured":"Dang N, Wairokpam T. Clinical case series on assessment of therapeutic efficacy of saroglitazar in MASLD patients. Asian J of Med Heal. 2024, 22 (9):11-18. 10.9734\/ajmah\/2024\/v22i91085","journal-title":"Asian J of Med Heal"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1002\/jgh3.12878","article-title":"Efficacy and safety of saroglitazar in real-world patients of non-alcoholic fatty liver disease with or without diabetes including compensated cirrhosis: A tertiary care center experience","volume":"7","author":"Chaudhuri S","year":"2023","unstructured":"Chaudhuri S, Dutta A, Chakraborty SB. Efficacy and safety of saroglitazar in real-world patients of non-alcoholic fatty liver disease with or without diabetes including compensated cirrhosis: A tertiary care center experience. JGH Open. 2023, 7:215-20. 10.1002\/jgh3.12878","journal-title":"JGH Open"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ihj.2015.02.007","article-title":"Observational study to evaluate the safety and efficacy of saroglitazar in Indian diabetic dyslipidemia patients","volume":"67","author":"Shetty SR","year":"2015","unstructured":"Shetty SR, Kumar S, Mathur RP, et al.. Observational study to evaluate the safety and efficacy of saroglitazar in Indian diabetic dyslipidemia patients. Indian Heart J. 2015, 67:23-6. 10.1016\/j.ihj.2015.02.007","journal-title":"Indian Heart J"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.focha.2023.100335","article-title":"Metabolic syndrome: Risk factors, diagnosis, pathogenesis, and management with natural approaches","volume":"3","author":"Mohamed SM","year":"2023","unstructured":"Mohamed SM, Shalaby MA, El-Shiekh RA, et al.. Metabolic syndrome: Risk factors, diagnosis, pathogenesis, and management with natural approaches. Food Chem Adv. 2023, 3:100335. 10.1016\/j.focha.2023.100335","journal-title":"Food Chem Adv"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2019.04.030","article-title":"Multitarget PPAR\u03b3 agonists as innovative modulators of the metabolic syndrome","volume":"173","author":"Ammazzalorso A","year":"2019","unstructured":"Ammazzalorso A, Maccallini C, Amoia P, Amoroso R. Multitarget PPAR\u03b3 agonists as innovative modulators of the metabolic syndrome. Eur J Med Chem. 2019, 173:261-73. 10.1016\/j.ejmech.2019.04.030","journal-title":"Eur J Med Chem"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jlr.2022.100233","article-title":"Saroglitazar is noninferior to fenofibrate in reducing triglyceride levels in hypertriglyceridemic patients in a randomized clinical trial","volume":"63","author":"Rodriguez-Gutierrez R","year":"2022","unstructured":"Rodriguez-Gutierrez R, Gonz\u00e1lez JG, Parmar D, et al.. Saroglitazar is noninferior to fenofibrate in reducing triglyceride levels in hypertriglyceridemic patients in a randomized clinical trial. J Lipid Res. 2022, 63:100233. 10.1016\/j.jlr.2022.100233","journal-title":"J Lipid Res"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12175674","article-title":"Dual PPR\u03b1\u03d2 agonists for the management of dyslipidemia: a systematic review and meta-analysis of randomized clinical trials","volume":"12","author":"Menezes Junior AD","year":"2023","unstructured":"Menezes Junior AD, Oliveira VM, Oliveira IC, et al.. Dual PPR\u03b1\u03d2 agonists for the management of dyslipidemia: a systematic review and meta-analysis of randomized clinical trials. J Clin Med. 2023, 12:10.3390\/jcm12175674","journal-title":"J Clin Med"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-55466-3","article-title":"Effect of a dual PPAR \u03b1\/\u03b3 agonist on insulin sensitivity in patients of type 2 diabetes with hypertriglyceridemia- Randomized double-blind placebo-controlled trial","volume":"9","author":"Jain N","year":"2019","unstructured":"Jain N, Bhansali S, Kurpad AV, et al.. Effect of a dual PPAR \u03b1\/\u03b3 agonist on insulin sensitivity in patients of type 2 diabetes with hypertriglyceridemia- Randomized double-blind placebo-controlled trial. Sci Rep. 2019, 9:19017. 10.1038\/s41598-019-55466-3","journal-title":"Sci Rep"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ihj.2017.02.020","article-title":"Recent trends in epidemiology of dyslipidemias in India","volume":"69","author":"Gupta R","year":"2017","unstructured":"Gupta R, Rao RS, Misra A, Sharma SK. Recent trends in epidemiology of dyslipidemias in India. Indian Heart J. 2017, 69:382-92. 10.1016\/j.ihj.2017.02.020","journal-title":"Indian Heart J"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.9065","article-title":"An observational study of reduction in glycemic parameters and liver stiffness by saroglitazar 4 mg in patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease","volume":"12","author":"Mitra A","year":"2020","unstructured":"Mitra A. An observational study of reduction in glycemic parameters and liver stiffness by saroglitazar 4 mg in patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease. Cureus. 2020, 12:e9065. 10.7759\/cureus.9065","journal-title":"Cureus"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.35248\/2155-6156.19.10.819","article-title":"A prospective, multicentre, single-arm clinical study to evaluate the effect of Saroglitazar on non-high-density lipoprotein cholesterol in patients with diabetic dyslipidaemia inadequately controlled with diet, exercise, and statin\u2014the GLIDDER study","volume":"10","author":"Kaul U","year":"2019","unstructured":"Kaul U, Priyadarshini A, Ranjan K, Vineeth B. A prospective, multicentre, single-arm clinical study to evaluate the effect of Saroglitazar on non-high-density lipoprotein cholesterol in patients with diabetic dyslipidaemia inadequately controlled with diet, exercise, and statin\u2014the GLIDDER study. J Diabetes Metab. 2019, 10:819. 10.35248\/2155-6156.19.10.819","journal-title":"J Diabetes Metab"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1177\/1932296813518680","article-title":"A multicenter, prospective, randomized, double-blind study to evaluate the safety and efficacy of Saroglitazar 2 and 4 mg compared to pioglitazone 45 mg in diabetic dyslipidemia (PRESS V)","volume":"8","author":"Pai V","year":"2014","unstructured":"Pai V, Paneerselvam A, Mukhopadhyay S, et al.. A multicenter, prospective, randomized, double-blind study to evaluate the safety and efficacy of Saroglitazar 2 and 4 mg compared to pioglitazone 45 mg in diabetic dyslipidemia (PRESS V). J Diabetes Sci Technol. 2014, 8:132-41. 10.1177\/1932296813518680","journal-title":"J Diabetes Sci Technol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-78342-x","article-title":"Saroglitazar in patients with non-alcoholic fatty liver disease and diabetic dyslipidemia: a prospective, observational, real world study","volume":"10","author":"Goyal O","year":"2020","unstructured":"Goyal O, Nohria S, Goyal P, et al.. Saroglitazar in patients with non-alcoholic fatty liver disease and diabetic dyslipidemia: a prospective, observational, real world study. Sci Rep. 2020, 10:21117. 10.1038\/s41598-020-78342-x","journal-title":"Sci Rep"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000000388","article-title":"Histologic findings of advanced fibrosis and cirrhosis in patients with nonalcoholic fatty liver disease who have normal aminotransferase levels","volume":"114","author":"Gawrieh S","year":"2019","unstructured":"Gawrieh S, Wilson LA, Cummings OW, et al.. Histologic findings of advanced fibrosis and cirrhosis in patients with nonalcoholic fatty liver disease who have normal aminotransferase levels. Am J Gastroenterol. 2019, 114:1626-35. 10.14309\/ajg.0000000000000388","journal-title":"Am J Gastroenterol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jceh.2024.101398","article-title":"A prospective randomised comparative four-arm intervention study of efficacy and safety of saroglitazar and vitamin E in patients with non-alcoholic fatty liver disease (NAFLD)\/non-alcoholic steatohepatitis (NASH)-SVIN TRIAL","volume":"14","author":"Mir BA","year":"2024","unstructured":"Mir BA, Sharma B, Sharma R, et al.. A prospective randomised comparative four-arm intervention study of efficacy and safety of saroglitazar and vitamin E in patients with non-alcoholic fatty liver disease (NAFLD)\/non-alcoholic steatohepatitis (NASH)-SVIN TRIAL. J Clin Exp Hepatol. 2024, 14:101398. 10.1016\/j.jceh.2024.101398","journal-title":"J Clin Exp Hepatol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.36922\/itps.3560","article-title":"The role of saroglitazar in the treatment of metabolic dysfunction-associated steatohepatitis in non-diabetic patients: A prospective observational study","volume":"7(4)","author":"Kumar JS","year":"2024","unstructured":"Kumar JS, Bhardwaj P, Chadha A, Kar P. The role of saroglitazar in the treatment of metabolic dysfunction-associated steatohepatitis in non-diabetic patients: A prospective observational study. INNOSC Thera Pharma Sci. 2024, 7(4):3560. 10.36922\/itps.3560","journal-title":"INNOSC Thera Pharma Sci"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1080\/00498254.2017.1413264","article-title":"Preclinical evaluation of saroglitazar magnesium, a dual PPAR-\u03b1\/\u03b3 agonist for treatment of dyslipidemia and metabolic disorders","volume":"48","author":"Patel H","year":"2018","unstructured":"Patel H, Giri P, Patel P, et al.. Preclinical evaluation of saroglitazar magnesium, a dual PPAR-\u03b1\/\u03b3 agonist for treatment of dyslipidemia and metabolic disorders. Xenobiotica. 2018, 48:1268-77. 10.1080\/00498254.2017.1413264","journal-title":"Xenobiotica"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.3450","article-title":"Pharmacokinetic, safety, and pharmacodynamic profiles of saroglitazar magnesium in cholestatic cirrhosis with hepatic impairment and participants with renal impairment","volume":"117","author":"Vuppalanchi R","year":"2025","unstructured":"Vuppalanchi R, Cruz MM, Momin T, et al.. Pharmacokinetic, safety, and pharmacodynamic profiles of saroglitazar magnesium in cholestatic cirrhosis with hepatic impairment and participants with renal impairment. Clin Pharmacol Ther. 2025, 117:240-9. 10.1002\/cpt.3450","journal-title":"Clin Pharmacol Ther"},{"key":"ref34","unstructured":"HealthPlix. Homepage. (2025). Accessed: July 26, 2025: https:\/\/healthplix.com."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/383292-evaluation-of-effectiveness-and-tolerability-of-saroglitazar-in-metabolic-disease-patients-of-india-a-retrospective-observational-electronic-medical-record-based-real-world-evidence-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T07:07:02Z","timestamp":1753859222000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/383292-evaluation-of-effectiveness-and-tolerability-of-saroglitazar-in-metabolic-disease-patients-of-india-a-retrospective-observational-electronic-medical-record-based-real-world-evidence-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,30]]},"references-count":34,"URL":"https:\/\/doi.org\/10.7759\/cureus.89028","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7,30]]}}}